The Use of Strontium-90 Beta Radiotherapy as Adjuvant Treatment for Conjunctival Melanoma. (31st January 2013)

• Record Type: Journal Article
• Authors: Cohen, Victoria M. L.; Papastefanou, Vasilios P.; Liu, S.; Stoker, Ian; Hungerford, John L.
• Other Names: Hara Akira Academic Editor.
• Is Part Of: Journal of oncology. Volume 2013(2013)
• Publication Date: 2013-01-31
• Subjects: Oncology -- Research -- Periodicals; Tumors -- Periodicals; Neoplasms; Oncology -- Research; Tumors; Periodicals; Periodicals; 616.994
• DOI: 10.1155/2013/349162
• Languages: English
• ISSNs: 1687-8450

Abstract

Abstract : Background/Aims . To report the safety and efficacy of strontium (Sr 90 ) beta radiotherapy as adjuvant treatment for conjunctival melanoma. Methods . A retrospective cohort study was undertaken from 1999 to 2007 of all patients who underwent Sr 90 beta radiotherapy for incompletely excised conjunctival melanoma. Failure of treatment was defined as recurrence of a conjunctival melanoma at the same location following beta radiotherapy. Results . Twenty patients underwent Sr 90 beta radiotherapy for incompletely excised conjunctival melanoma. Median follow-up interval was 59 months (8–152). All patients had conjunctival melanoma involving the bulbar conjunctiva. Underlying diagnoses included PAM with atypia in 60% (12 of 20), PAM without atypia in 15% (3 of 20), and de novo conjunctival melanoma in 25% (5 of 20). Following Sr 90 beta radiotherapy, in 90% (18 out of 20) local control was achieved and visual acuity was not affected in any patient. Three patients (15%) had dry eye symptoms, episcleritis, and descemetcoele, respectively. No cataract or secondary glaucoma was reported. Conclusions . Sr 90 treatment is a very effective adjuvant treatment after excisional biopsy and cryotherapy for conjunctival melanoma with a local success rate of 90%. The treatment is not associated with significant side effects and visual acuity is not affected.